|
Vol. 11.39 – 26 October, 2022
|
|
|
|
|
|
Researchers provided biochemical, genetic, and functional evidence that dynamics in ribosomal RNA (rRNA) 2′-O-methylation regulated leukemia stem cell activity in vivo. [Cancer Discovery]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Scientists showed that an antibody against cadherin proteins effectively suppressed blood-borne metastasis in mouse isogenic and xenograft models of triple-negative breast and pancreatic cancers. [Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
Bioinformatics analysis and immunohistochemical results showed that NQO1 was highly expressed in hepatocellular carcinoma (HCC) tissues. Overexpression of NQO1 promoted cell proliferation, epithelial-to-mesenchymal transition process, and angiogenesis of HCC cells. [Oncogene]
|
|
|
|
|
The authors showed an association between tissue factor expression and metastasis as well as cancer stemness in 574 breast cancer patients.
[Oncogene]
|
|
|
|
|
CircLRFN5 overexpression inhibited the cell viabilities, proliferation, neurosphere formation, stemness, and tumorigenesis of glioma stem cells via inducing ferroptosis. [Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
Using a lymphoma-specific sequencing panel, investigators assessed the prognostic and predictive utilities of circulating tumor DNA measurements before, during, and after first-line therapy.
[BMC Medicine]
|
|
|
|
|
Functional studies showed FBXO31 inhibited cell growth, migration, invasion, CSC properties, and epithelial-mesenchymal transition in vitro and impeded tumor growth in vivo. [Liver International]
|
|
|
|
|
Scientists found that the long noncoding RNA HOTAIR was highly expressed in breast CSCs. HOTAIR was required for breast CSC self-renewal and tumor propagation.
[Journal of Biological Chemistry]
|
|
|
|
|
Researchers determined that the most abundantly expressed anti-apoptotic Bcl-2 family members, Bcl-xL and Mcl-1, were the most relevant in regulating patient-derived glioma stem cell survival.
[Scientific Reports]
|
|
|
|
|
Investigators screened transcription factors and found that RELA, a subunit of nuclear factor kappaB, was critical for CD271 transcription in cancer cells. [Scientific Reports]
|
|
|
|
|
|
|
Scientists present a practical overview for the selection of the most appropriate liquid biopsy assay, specifically focusing on circulating tumor DNA and how it may affect patient treatment and case management across multiple tumor types. [JAMA Oncology]
|
|
|
|
|
The authors discuss the effect of exosomes on signaling pathways associated with epithelial-mesenchymal transition (EMT) and CSCs, as well as possible therapeutic strategies of exosomes in cancer metastasis. [Life Sciences]
|
|
|
|
|
|
BriaCell Therapeutics Corp. announced the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT™, in combination with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer.
[BriaCell Therapeutics Corp.]
|
|
|
|
|
Bio-Path Holdings, Inc. announced the enrollment and dosing of the first patient in a Phase I/Ib clinical trial evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients. [Bio-Path Holdings, Inc.]
|
|
|
|
|
|
November 10 – 12, 2022 Bordeaux, France
|
|
|
|
|
|
|
Columbia University Irving Medical Center – New York, New York, United States
|
|
|
|
|
Ludwig Maximilians University of Munich – Munich, Germany
|
|
|
|
|
Beth Israel Deaconess Medical Center – Boston, Massachusetts, United States
|
|
|
|
|
Wellcome Genome Campus – Saffron Walden, England, United Kingdom
|
|
|
|
|
AstraZeneca – Gothenburg, Sweden
|
|
|
|
|